Drugs / double-mutant LT
double-mutant LT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01147445 | Sep 2010 → Jun 2012 | gastroenteritis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | double-mutant LT | “The rationale for using an E. coli heat labile enterotoxin (LT) (R192G/L211A) vaccine, also called double-mutant LT (dmLT), is that it is expected to be especially well...” NCT01147445 ↗ |
| Known as | dmLT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01147445 ↗ |
| Known as | LT(R192G/L211A) | “LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat labile enterotoxin.” NCT01147445 ↗ |
| Modality | Vaccine | “new candidate vaccine (dmLT) against ETEC (E. coli infection)” NCT01147445 ↗ |
| Route | Oral | “Vaccine dosage levels: 5, 25, 50, 100 micrograms as a single, oral dose.” NCT01147445 ↗ |